DexCom, Inc. DXCM
86.62
(0.85)
(0.97%)
as of 25 Sep
- Market cap
- $33.0B
- P/E
- 33.4×
Follow DXCM
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
DexCom, Inc. (DXCM) Operating cash flow
DexCom, Inc.'s operating cash flow for fiscal 2025 was $1.4B, up 45.6% from $989.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.7B. Over the past ten years it has ranged from $49.0M (fiscal 2015) to $1.4B (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 4 consecutive fiscal years. DexCom, Inc. ranks 8th of 149 Medical Devices companies by operating cash flow.
Operating cash flow, annual
Annual
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $1.4B | 45.60% |
| FY2024 | $989.5M | 32.20% |
| FY2023 | $748.5M | 11.80% |
| FY2022 | $669.5M | 51.30% |
| FY2021 | $442.5M | (6.96%) |
| FY2020 | $475.6M | 51.22% |
| FY2019 | $314.5M | 155.28% |
| FY2018 | $123.2M | 33.91% |
| FY2017 | $92.0M | 63.70% |
| FY2016 | $56.2M | 14.69% |
Quarterly
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $269.2M | (48.78%) |
| Mar 2026 | $525.6M | 78.78% |
| Dec 2025 | $294.0M | (55.45%) |
| Sep 2025 | $659.9M | 117.79% |
| 42 more quarters | Free account |
Against its own ten years
Low $49.0M
High $1.4B
Ten-year median
$442.5M
Current reading's percentile
100
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| BSX Boston Scientific Corporation compare | $4.5B |
| SNN Smith & Nephew SNATS, Inc. compare | $3.1B |
| PHG Koninklijke Philips N.V. compare | $2.6B |
| GEHC GE HealthCare Technologies Inc. compare | $2.1B |
| DXCM DexCom, Inc. | $1.7B |
| ZBH Zimmer Biomet Holdings, Inc. compare | $1.7B |
| EW Edwards Lifesciences Corporation compare | $1.7B |
| STE STERIS plc compare | $1.3B |
| PEN Penumbra, Inc. compare | $277.8M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on DXCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement